Who
Daniel Patrick O'Day
Chairman & CEO
Company insider
Files Form 4 as: Chairman & CEO, Gilead Sciences.
In numbers
- Trades disclosed
- 203
- Buys
- 0
- Sells
- 19
- Bought
- $0
- Sold
- $104.6M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 1 Mar 2019
- Last trade
- 1 Oct 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 May 2025 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Oct 2026filed 2 Oct 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $1.8M12,000 at $147.72 | filing |
| 1 Oct 2026filed 2 Oct 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $446K3,000 at $148.63 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —8,780 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $613K4,230 at $144.81 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,780 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,780 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code M | —8,780 | filing |
| 10 Sep 2026filed 11 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Code F | $613K4,230 at $144.81 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $236K1,600 at $147.51 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $1.2M7,992 at $148.36 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $808K5,408 at $149.38 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $236K1,600 at $147.51 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $1.2M7,992 at $148.36 | filing |
| 1 Sep 2026filed 2 Sep 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $808K5,408 at $149.38 | filing |
| 3 Aug 2026filed 4 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $869K6,700 at $129.66 | filing |
| 3 Aug 2026filed 4 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $1.0M7,700 at $130.80 | filing |
| 3 Aug 2026filed 4 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $79K600 at $131.34 | filing |
| 3 Aug 2026filed 4 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $869K6,700 at $129.66 | filing |
| 3 Aug 2026filed 4 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $1.0M7,700 at $130.80 | filing |
| 3 Aug 2026filed 4 Aug 2026 | GILD Gilead SciencesBiotechnology | SEC FORM 4 Sold | $79K600 at $131.34 | filing |
News
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?GILD · aol.com · 25 Oct 20267,751 Shares in Gilead Sciences, Inc. $GILD Bought by NBT Bank N.A.GILD · dailypolitical.com · 24 Oct 2026Gilead Sciences (GILD) vs. AMGN and VRTX: Can Oncology Growth and HIV Strength Drive a New Growth Era Beyond Acquisitions?GILD · insidermonkey.com · 22 Oct 2026
0 headlines in the last 90 days name Daniel Patrick O'Day; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.